Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century.
Sara MheidStefan AllenSylvia S W NgWilliam A HallNina N SanfordTodd A AguileraAhmed M ElamirRana BahijMartijn P W IntvenGanesh RadhakrishnaIssa MohamadJeremy De LeonHendrick TanShirley LewisCihan GaniTeo StanecuVeronica Dell'AcquaAli HosniPublished in: Current oncology (Toronto, Ont.) (2023)
The utilization of stereotactic body radiation therapy for the treatment of liver metastasis has been widely studied and has demonstrated favorable local control outcomes. However, several predictive factors play a crucial role in the efficacy of stereotactic body radiation therapy, such as the number and size (volume) of metastatic liver lesions, the primary tumor site (histology), molecular biomarkers (e.g., KRAS and TP53 mutation), the use of systemic therapy prior to SBRT, the radiation dose, and the use of advanced technology and organ motion management during SBRT. These prognostic factors need to be considered when clinical trials are designed to evaluate the efficacy of SBRT for liver metastases.
Keyphrases
- radiation therapy
- prognostic factors
- liver metastases
- clinical trial
- radiation induced
- small cell lung cancer
- locally advanced
- squamous cell carcinoma
- type diabetes
- randomized controlled trial
- metabolic syndrome
- high speed
- mesenchymal stem cells
- phase ii
- combination therapy
- mass spectrometry
- smoking cessation
- drug induced
- glycemic control
- double blind